novo nordisk obesity - Search News

Novo Nordisk's next-gen obesity drug Cagrisema

Hosted on MSN · 19h

Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion from its market value.

The Motley Fool on MSN · 3d

Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy, to shame. Let's look deeper into these results and what they could mean for investors.

Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk beats in Q4

The New York Times · 14h

Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

YAHOO!Finance · 2h

Novo Nordisk AS (NVO) Q4 2024 Earnings Call Highlights: Robust Growth in Sales and Profit Amid ...

Novo Nordisk AS (NVO) reports a strong 26% increase in sales and operating profit, with significant growth in obesity care and strategic acquisitions enhancing future market supply.

FiercePharma · 18h

Novo Nordisk predicts milder growth in 2025 after obesity star Wegovy doubles sales in Q4

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between 16% and 24%—a range that analysts at ODDO BHF called “wide but reassuring.”

18h

Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow

Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

21hon MSN

Novo Nordisk cashes in on obesity and diabetes drugs as profits swell

Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...

12d

Novo Nordisk Shares Surge on New Obesity Drug Results

Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results